Search Results - "MILLER, D. P"

Observations following discontinuation of long-term denosumab therapy by McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., Lewiecki, E. M.

“…Summary Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not…”
Get full text

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates by Miller, P. D, Pannacciulli, N, Brown, J. P, Czerwinski, E, Nedergaard, B. S, Bolognese, M. A, Malouf, J, Bone, H. G, Reginster, J.-Y, Singer, A, Wang, C, Wagman, R. B, Cummings, S. R

“…Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the…”
Get full text

PINP as a biological response marker during teriparatide treatment for osteoporosis by Krege, J. H., Lane, N. E., Harris, J. M., Miller, P. D.

“…Postmenopausal women with severe osteoporosis may require treatment with the bone anabolic drug teriparatide. While changes in bone mineral density (BMD) are…”
Get full text

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial by McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.

“…Summary In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent…”
Get full text

Magneto-optical characterization of TCO films using standard and enhanced configurations by Syed, M., Reza, S. A., Miller, P. D., Roop, B.

“…Thin film samples like transparent conducting oxides (TCO) are typically investigated using measurements like Hall Effect and 4-point probe measurements. We…”
Get full text

Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment by MILLER, P. D, SCHWARTZ, E. N, CHEN, P, MISURSKI, D. A, KREGE, J. H

“…The prevalence of both osteoporosis and renal impairment increases with age. Using data from the Fracture Prevention Trial, the safety and efficacy of…”
Get full text

The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99 : results from the National Osteoporosis Risk Assessment (NORA) by SIRIS, E. S, BRENNEMAN, S. K, BARRETT-CONNOR, E, MILLER, P. D, SAJJAN, S, BERGER, M. L, CHEN, Y.-T

“…This study evaluates the effect of age and bone mineral density (BMD) on the absolute, excess, and relative risk for osteoporotic fractures at the hip, wrist,…”
Get full text

Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) by Barrett-Connor, E, Weiss, T. W, McHorney, C. A, Miller, P. D, Siris, E. S

“…Summary Using data from 66,134 postmenopausal women enrolled in the National Osteoporosis Risk Assessment (NORA) study, more than half of whom were less than…”
Get full text

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study by Reginster, J-Y, Adami, S, Lakatos, P, Greenwald, M, Stepan, J J, Silverman, S L, Christiansen, C, Rowell, L, Mairon, N, Bonvoisin, B, Drezner, M K, Emkey, R, Felsenberg, D, Cooper, C, Delmas, P D, Miller, P D

“…Background: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal…”
Get full text

A Study of the Direct Spectral Transform for the Defocusing Davey‐Stewartson II Equation the Semiclassical Limit by Assainova, O., Klein, C., McLaughlin, K. D. T.‐R., Miller, P. D.

“…The defocusing Davey‐Stewartson II equation has been shown in numerical experiments to exhibit behavior in the semiclassical limit that qualitatively resembles…”
Get full text

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis by Miller, P. D, Derman, R. J

“…Pharmacologic osteoporosis therapy, particularly anti-resorptives, is recommended in postmenopausal women with clinical risk factors for fracture. Treatment…”
Get full text

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes by Miller, P D E, de Silva, T I, Skinner, R, Gilleece, M, Peniket, A, Hamblin, A, Greenfield, D, Anthias, C, Peggs, K, Madrigal, A, Snowden, J A

Get full text

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years by Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.

“…Summary Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years,…”
Get full text

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial by Harris, Steven T, Watts, Nelson B, Genant, Harry K, McKeever, Clark D, Hangartner, Thomas, Keller, Michael, Chesnut III, Charles H, Brown, Jacques, Eriksen, Erik F, Hoseyni, Mohammad S, Axelrod, Douglas W, Miller, Paul D, for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

“…CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but,…”
Get full text

Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) by Barrett-Connor, E., Sajjan, S. G., Siris, E. S., Miller, P. D., Chen, Y.-T., Markson, L. E.

“…Summary The short-term association between wrist-fracture history and future fracture has not been simultaneously compared between younger and older…”
Get full text

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker by Pazianas, M., Blumentals, W. A., Miller, P. D.

“…Summary Using jaw surgery as a surrogate marker for osteonecrosis of the jaw, this exploratory study did not find that the risk of jaw surgery was…”
Get full text

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data by Cranney, A, Wells, G. A, Yetisir, E, Adami, S, Cooper, C, Delmas, P. D, Miller, P. D, Papapoulos, S, Reginster, J.-Y, Sambrook, P. N, Silverman, S, Siris, E, Adachi, J. D

“…Summary This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for…”
Get full text

Antifracture efficacy of antiresorptive agents are related to changes in bone density by WASNICH, R. D, MILLER, P. D

“…There is a current debate about the extent to which antifracture efficacy of antiresorptive drugs are related to changes in bone mineral density (BMD). In…”
Get full text

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study by Miller, P. D., Recker, R. R., Reginster, J.-Y., Riis, B. J., Czerwinski, E., Masanauskaite, D., Kenwright, A., Lorenc, R., Stakkestad, J. A., Lakatos, P.

“…Summary The long-term efficacy and safety of once-monthly ibandronate were studied in this extension to the 2-year Monthly Oral Ibandronate in Ladies (MOBILE)…”
Get full text

Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option? by Lubwama, R., Nguyen, A., Modi, A., Diana, C., Miller, P. D.

“…Summary Bisphosphonates are the first-line treatment for osteoporotic (OP) women; however, therapy is not recommended in severe renal impairment (RI). This…”
Get full text